Tiltan Pharma

Anti-angiogenic and Immune Modulatory Platforms for Cancer Treatment

Health Tech & Life Sciences
Non Active, Sep 2019 ceased to operate

Company Overview

Snapshot

Founded in January 2006 by Yigal Stav and Shmuel (Muli) Ben-Sasson, Tiltan Pharma operated with 11–50 employees. The company raised $1.5 million across one funding round from Integra Holdings. In February 2014, Tiltan Pharma secured $1.5 million in funding.

Business overview

Tiltan Pharma is a biopharmaceutical company focused on developing anti-angiogenic and immune modulatory platforms for cancer treatment. Its core product, TL-118, is an oral drug combination that repurposes four approved drugs to act as an anticancer therapy with anti-angiogenic and immune modulatory properties. The company serves the pharmaceutical and healthcare industries, specifically targeting oncology and cancer treatment markets.

Company Intelligence Q&A

What is Tiltan Pharma's primary focus?
Tiltan Pharma is focused on developing proprietary anti-angiogenic and immune modulatory platforms for the treatment of cancer.
What is TL-118?
TL-118 is Tiltan Pharma's leading product, an oral drug combination with anticancer, anti-angiogenic, and immune modulatory properties. It repurposes four approved drugs for cancer therapy in a low-dose, high-frequency regimen.
When was Tiltan Pharma founded?
Tiltan Pharma was founded in January 2006.
Who are the founders of Tiltan Pharma?
Tiltan Pharma was co-founded by Yigal Stav and Shmuel (Muli) Ben-Sasson.
What was the last reported funding event for Tiltan Pharma?
In February 2014, Tiltan Pharma raised $1.5 million in a Seed funding round from Integra Holdings.

External links